Maguran

Doxazosin, the active ingredient in Maguran, is an alpha‑1 adrenergic receptor antagonist presented as an oral tablet for oral use. It is used to treat hypertension and benign prostatic hyperplasia in adult patients. GNH USA supplies Maguran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the alpha‑1 adrenergic pathway to manage cardiovascular and urological conditions.

Hypertension: lowers blood pressure by causing vasodilation and reducing peripheral vascular resistance. Benign prostatic hyperplasia (BPH): relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing obstruction.

Doxazosin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or tiredness. - Nasal congestion or runny nose. - Peripheral edema. - Gastrointestinal discomfort.

Serious or Rare Side Effects: - Marked hypotension or syncope. - Priapism (prolonged erection). - Severe allergic reactions, including rash, itching, or swelling. - Angioedema affecting face, lips, or throat. - Liver function abnormalities. - Cardiac arrhythmias (rare).

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: assess for orthostatic changes after the first dose. Assess renal and hepatic function: dose adjustments may be needed in impairment. Review concomitant antihypertensives: avoid excessive blood pressure lowering. Caution in patients with a history of syncope or severe cardiovascular disease. Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Doxazosin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., prazosin, terazosin) – additive hypotensive effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – increased plasma levels. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil) – risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics – may enhance orthostatic hypotension. - Other antihypertensives (beta‑blockers, ACE inhibitors) – monitor blood pressure. - NSAIDs – may blunt antihypertensive response. - Lithium – monitor serum lithium levels. - Antidepressants with serotonergic activity – watch for blood pressure changes.